All In Biotech

Drug Trial Radar · NCT00863499

International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder

International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.

Last checked: Nov 19, 2026Latest source record: Jul 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,344

Planned (sponsor's estimate)

Start

Oct 2009

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
BRC Operations Pty. Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2. identify brain, genetic and cognitive markers that predict treatment response to short-acting methylphenidate in children and adolescents diagnosed with Attention Deficit/Hyperactivity Disorder.

Conditions

  • Attention Deficit/Hyperactivity Disorder

Interventions

  • Short Acting MethylphenidateDrug

    Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.

  • Long Acting MethylphenidateDrug

    Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalize' with acute drug treatment in ADHD.Time frame: 6 weeks

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Shanti Clinical Trials

    Colton, California

  • Center for Healing the Human Spirit

    Tarzana, California

  • Brain Resource Center

    Englewood Cliffs, New Jersey

  • Brain Resource Center

    New York, New York

  • Skyland Behavioral Health Associates , P.A.

    Asheville, North Carolina

  • Brain Dynamics Centre

    Westmead, New South Wales, Australia

  • Brainclinics Diagnostics B.V.

    Nijmegen, Gelderland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.